Actinic cheilitis and squamous cell carcinoma of the lip: Clinical, histopathological and immunogenetic aspects;Queilite actínica e carcinoma espinocelular do lábio: Aspectos clínicos, histopatológicos e imunogenéticos

Anais Brasileiros de Dermatologia

Volumn 87, Issue 1, 2012, Pages 105-114

  Vieira, Renata Aparecida Martinez Antunes Ribeiro ^a   Minicucci, Eliana Maria ^a   Marques, Mariangela Esther Alencar ^a   Marques, Silvio Alencar ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Carcinoma; Cheilitis; Cyclin D1; Cyclin dependent kinase inhibitor proteins; Protooncogene proteins c bcl 2; Squamous cell; Tumor suppressor protein p53

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FLUOROURACIL; IMIQUIMOD; INDUCIBLE NITRIC OXIDE SYNTHASE; KERATIN; MASPIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; SURVIVIN; TRICHLOROACETIC ACID;

ACTINIC CHEILITIS; CANCER GROWTH; CANCER PROGNOSIS; CARBON DIOXIDE LASER; CELL CYCLE ARREST; CELL PROLIFERATION; CHEILITIS; CLINICAL FEATURE; CRYOTHERAPY; DNA DAMAGE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; LASER SURGERY; LIP CARCINOMA; LIP SQUAMOUS CELL CARCINOMA; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 84862187864     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000100013     Document Type: Review

References (58)

1. Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2010: incidência de câncer no Brasil. Rio de Janeiro: INCA. 2009. 98 p.
2. Shiu MN, Chen THH. Intervention efficacy and malignant transformation to oral cancer among patients with leukoplakia (review). Oncol Rep. 2003;10:1683-92.
3. Carinci F, Lo Muzio L, Piattelli A, Rubini C, Palmieri A, Stabellini G, et al. Genetic portrait of mild and severa lingual dysplasia. Oral Oncol. 2005;41:365-74.
4. Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Radiat Res. 1998;150: S30-41.
5. Biaglow JE. The effects of ionizing radiation on mammalian cells. In: Farhataziz, Rogers MAJ, editors Radiation Chemistry: principles and applications. New York: VHC Publishers; 1987. p. 527-63.
6. Boothman DA, Meyers M, Odegaard E Wang M. Altered G1 checkpoint control determines adaptive survival responses to ionizing radiation. Mutat Res. 1996;358:143-53.
7. Picascia DD, Robinson JK. Actinic cheilitis: a review of the etiology, differential diagnosis, and treatment. J Am Acad Dermatol. 1987;17:255-64.
8. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80.
9. Markopoulos A, Albanidou-Farmaki E, Kayavis I. Actinic cheilitis: clinical and pathologic characteristics in 65 cases. Oral Dis. 2004;10:212-6.
10. Ochsenius G, Ormeño A, Godoy L, Rojas R. [A retrospective study of 232 cases of lip cancer and pre cancer in Chilean patients. Clinical-histological correlation]. Rev Med Chil. 2003;131:60-6.
11. Bouquot JE. Oral leukoplakia and erythroplakia: a review and update. Pract Periodontics Aesthet Dent. 1994;6:9-17.
12. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000;6:1702-10.
13. Cooke BE, Tapper-Jones L. Recognition ecognition of oral cancer. Causes of delay. Br Dent J. 1977;142:96-8.
14. Menta Simonsen Nico M, Rivitti EA, Lourenco SV. Actinic cheilitis: histologic study of the entire vermilion and comparison with previous biopsy. J Cutan Pathol. 2007;34:309-14.
15. Robinson JK. Actinic cheilitis. A prospective study comparing four treatment methods. Arch Otolaryngol Head Neck Surg. 1989;115:848-52.
16. Sanchez-Conejo-Mir J, Perez Bernal AM, Moreno-Gimenez JC, Camacho-Martinez F. Follow-up of vermilionectomies: evaluation of the technique. J Dermatol Surg Oncol. 1986;12:180-4.
17. Rossoe EWT, Tebcherani AJ, Sittart JA, Pires MC. Queilite actinica: avaliação comparativa estética e funcional entre as vermelhectomias clássica e em W-plastia. An Bras Dermatol. 2011;86:65-73.
18. Orenstein A, Goldan O, Weissman O, Winkler E, Haik J. A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J Cosmet Laser Ther. 2007;9:23-5.
19. Greenberg HL, Cohen JL, Rosen T, Orengo I. Severe reaction to 5% imiquimod crem with excellent clinical and cosmetic outcomes. J Drugs Dermatol. 2007;6:452-8
20. Rossi R, Assad GB, Buggiani G, Lotti T. Photodynamic therapy: treatment of choice for actinic cheilitis? Dermatol Ther. 2008;21:412-5.
21. dos Santos LR, Cernea CR, Kowalski LP, Carneiro PC, Soto MN, Nishio S, et al. Squamous-cell carcinoma of the lower lip: a retrospective study of 58 patients. Sao Paulo Med J. 1996;114:1117-26.
22. Zitsch RP 3rd, Park CW, Renner GJ, Rea JL. Outcome analysis for lip carcinoma. Otolaryngol Head Neck Surg. 1995;113:589-96.
23. Scully C. Oral manifestations associated with human immunodeficiency virus (HIV) infection in developing countries--are there differences from developed countries? Oral Dis. 2000;6:395.
24. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-45. Bilkay U, Kerem 25. erem H, Ozek C, Gundogan H, Guner U, Gurler T, et al. Management of lower lip cancer: a retrospective analysis of 118 patients and review of the literature. Ann Plast Surg. 2003;50:43-50.
25. Bentley JM, Barankin B, Lauzon GJ. Paying more than lip service to lip lesions. Can Fam Physician. 2003;49:1111-6.
26. McGregor GI, Davis NL, Hay JH. Impact of cervical lymph node metastases from squamous cell cancer of the lip. Am J Surg. 1992;163:469-71.
27. Abreu MA, Silva OM, Neto Pimentel DR, Hirata CH, Weckx LL, Alchorne MM, et al. Actinic cheilitis adjacent to squamous carcinoma of the lips as an indicator of prognosis. Braz J Otorhinolaryngol. 2006;72:767-71
28. Winn DM. Diet and nutrition in the etiology of oral cancer. Am J Clin Nutr. 1995;61:437S-45S.
29. Lindqvist C, Teppo L, Pukkala E. Occupations with low risk of lip cancer show high risk of skin cancer of the head. Community Dent Oral Epidemiol. 1981;9:247-50.
30. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60:183-9.
31. Awde JD, Kogon SL, Morin RJ. Lip cancer: a review. J Can Dent Assoc. 1996;62: 634-6.
32. Ministério da Saúde. Secretaria de Atenção à Saúde. Instituto Nacional do Câncer. TNM: classificação de tumores malignos. 6 ed. Rio de Janeiro: INCA; 2004. 254 p.
33. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005;55:242-58.
34. Costa Ade L, Pereira JC, Nunes AA, Arruda Mde L. [Correlation between TNM classification, histological grading and anatomical location in oral squamous cell carcinoma]. Pesqui Odontol Bras. 2002;16:216-20.
35. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med. 1989;18:432-7.
36. Bankfalvi A, Piffko J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med. 2000;29:291-8.
37. Veness MJ, Ong C, Cakir B, Morgan G. Squamous cell carcinoma of the lip. Patterns of relapse and outcome: Reporting the Westmead Hospital experience, 1980-1997. Australas Radiol. 2001;45:195-9.
38. Zimmermann KC, Green DR. How cells die: apoptosis pathways. J Allergy Clin Immunol. 2001;108(4 Suppl):S99-103.
39. Loro LL, Vintermyr OK, Johannessen AC. Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med. 2003;32:125-38.
40. Rotter V, Prokocimer M. p53 and human malignancies. Adv Cancer Res. 1991;57:257-72.
41. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5-8.
42. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005;26:1657-67.
43. Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol. 1998;184:360-8.
44. Crosthwaite N, Teale D, Franklin C, Foster GA, Stringer BM. p53 protein expression in malignant, pre-malignant and non-malignant lesions of the lip. J Clin Pathol. 1996;49:648-53.
45. Neto Pimentel DR, Michalany N, Alchorne M, Abreu M, Borra RC, Weckx L. Actinic cheilitis: histopathology and p53. J Cutan Pathol. 2006;33:539-44.
46. Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, et al. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol. 2003;16: 944-50.
47. Horta MC, de Assis LA, de Souza AF, de Araújo VC, Gomez RS, Aguiar MC. p53 and p21WAF1/CIP1 overexpression at the invasive front of lower lip squamous cell carcinoma. J Oral Pathol Med. 2007;36:88-92.
48. Martínez A, Brethauer U, Borlando J, Spencer ML, Rojas IG. Epithelial expression of p53, mdm-2 and p21 in normal lip and actinic cheilitis. Oral Oncol. 2008;44:878-83.
49. Nemes JA, Nemes Z, Marton IJ. p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2005;34:274-9.
50. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001;34:207-12.
51. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, et al. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett. 2005;225: 27-33.
52. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78:233-9.
53. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci U S A. 1992;89:3030-4.
54. Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD. Does type II nitric oxide synthase expression correlate with cellular proliferation in oral squamous cell carcinoma and dysplasia? Head Neck. 2001;23:217-22.
55. Brennan PA, Palacios-Callender M, Umar T, Tant S, Langdon JD. Expression of type 2 nitric oxide synthase and p21 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2002;31:200-5.
56. Cory S, Adams JM. The bcel-2 family: regulators of the cellular life-or-death switch. Nature Rev. 2002:2:647-56.
57. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol. 2009;21:516-23.
58. Fontes A, Sousa SM, Santos E, Martins MT. The severity of epithelial dysplasia is associated with loss of maspin expression in actinic cheilitis. J Cutan Pathol. 2009;36:1151-56.